Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: The impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4491-4500

  Lin, Hai Shu ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bioavailability; Cyclodextrins; Dose proportionality; Oral absorption; Pharmacokinetics; Repeated dosing; Resveratrol; Resveratrol trimethyl ether; Solubility

Indexed keywords

METHYL BETA CYCLODEXTRIN; RESVERATROL; 3,4',5-TRIMETHOXYSTILBENE; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; METHYL-BETA-CYCLODEXTRIN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; DRUG ADMINISTRATION; EVALUATION STUDY; GASTROINTESTINAL ABSORPTION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; EXCIPIENTS; GASTROINTESTINAL ABSORPTION; HALF-LIFE; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STILBENES; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052261942     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22588     Document Type: Article

References (60)

1. Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506.
2. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, Estrela JM. 2002. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-398.
3. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369-373.
4. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
5. Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382.
6. Wenzel E, Somoza V. 2005. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49:472-481.
7. Blair GE, Cassady JM, Robbers JE, Tyler VE, Raffauf RF. 1969. Chemical investigation of Virola species. I. Isolation of 3, 4', 5-trimethoxy-trans-stilbene, otobaene, and hydroxyotobain from Virola cuspidata. Phytochemistry 8:497-500.
8. MacRae WD, Towers GHN. 1985. Nonalkaloidal constituents of Virola elongata bark. Phytochemistry 24:561-566.
9. Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E. 1992. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3, 4, 5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem 35:2293-2306.
10. Weng CJ, Wu CF, Huang HW, Wu CH, Ho CT, Yen GC. 2010. Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem 58:2886-2894.
11. Pan MH, Lin CL, Tsai JH, Ho CT, Chen WJ. 2010. 3, 5, 3', 4', 5'-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J Agric Food Chem 58:226-234.
12. Wang TT, Schoene NW, Kim YS, Mizuno CS, Rimando AM. 2010. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 54:335-344.
13. Yoo KM, Kim S, Moon BK, Kim SS, Kim KT, Kim SY, Choi SY. 2006. Potent inhibitory effects of resveratrol derivatives on progression of prostate cancer cells. Arch Pharm (Weinheim) 339:238-241.
14. Bader Y, Madlener S, Strasser S, Maier S, Saiko P, Stark N, Popescu R, Huber D, Gollinger M, Erker T, Handler N, Szakmary A, Jager W, Kopp B, Tentes I, Fritzer-Szekeres M, Krupitza G, Szekeres T. 2008. Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. Oncol Rep 19:801-810.
15. Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C. 2007. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z Naturforsch [C] 62:189-195.
16. Pan MH, Gao JH, Lai CS, Wang YJ, Chen WM, Lo CY, Wang M, Dushenkov S, Ho CT. 2008. Antitumor activity of 3, 5, 4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog 47:184-196.
17. Simoni D, Roberti M, Invidiata FP, Aiello E, Aiello S, Marchetti P, Baruchello R, Eleopra M, Di Cristina A, Grimaudo S, Gebbia N, Crosta L, Dieli F, Tolomeo M. 2006. Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett 16:3245-3248.
18. Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, Suh N, Rimando AM. 2010. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer. Eur J Med Chem 45:3702-3708.
19. Yang YT, Weng CJ, Ho CT, Yen GC. 2009. Resveratrol analog-3, 5, 4'-trimethoxy-trans-stilbene inhibits invasion of human lung adenocarcinoma cells by suppressing the MAPK pathway and decreasing matrix metalloproteinase-2 expression. Mol Nutr Food Res 53:407-416.
20. Alex D, Leong EC, Zhang ZJ, Yan GT, Cheng SH, Leong CW, Li ZH, Lam KH, Chan SW, Lee SM. 2010. Resveratrol derivative, trans-3, 5, 4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem 109:339-346.
21. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M. 2005. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3, 5, 4'-trimethoxystilbene. Mol Pharmacol 67:1451-1459.
22. Spatafora C, Basini G, Baioni L, Grasselli F, Sofia A, Tringali C. 2009. Antiangiogenic resveratrol analogues by mild m-CPBA aromatic hydroxylation of 3, 5-dimethoxystilbenes. Nat Prod Commun 4:239-246.
23. Basini G, Tringali C, Baioni L, Bussolati S, Spatafora C, Grasselli F. 2010. Biological effects on granulosa cells of hydroxylated and methylated resveratrol analogues. Mol Nutr Food Res 54 Suppl 2:S236-243.
24. Matsuda H, Tewtrakul S, Morikawa T, Yoshikawa M. 2004. Anti-allergic activity of stilbenes from Korean rhubarb (Rheum undulatum L.): structure requirements for inhibition of antigen-induced degranulation and their effects on the release of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem 12:4871-4876.
25. Yuan Q, Peng J, Liu SY, Wang CJ, Xiang DX, Xiong XM, Hu CP, Li YJ. 2010. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway. Clin Exp Pharmacol Physiol 37:630-635.
26. Deng YH, Alex D, Huang HQ, Wang N, Yu N, Wang YT, Leung GP, Lee SM. 2010. Inhibition of TNF-alpha-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3, 5, 4'-trimethoxystilbene. Phytother Res 25:451-457.
27. Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, Li J, Wu CF. 2008. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Chem Biol Interact 174:51-59.
28. Cho DI, Koo NY, Chung WJ, Kim TS, Ryu SY, Im SY, Kim KM. 2002. Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action. Life Sci 71:2071-2082.
29. Li L, Luo XJ, Liu YZ, Zhang YS, Yuan Q, Tan N, Xiang DX, Peng J. 2010. The role of the DDAH-ADMA pathway in the protective effect of resveratrol analog BTM-0512 on gastric mucosal injury. Can J Physiol Pharmacol 88:562-567.
30. Rivera H, Shibayama M, Tsutsumi V, Perez-Alvarez V, Muriel P. 2008. Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat. J Appl Toxicol 28:147-155.
31. Lin HS, Ho PC. 2009. A rapid HPLC method for the quantification of 3, 5, 4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J Pharm Biomed Anal 49:387-392.
32. Davis ME, Brewster ME. 2004. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3:1023-1035.
33. National Advisory Committee for Laboratory Animal Research. 2004. Guidelines on the Care and Use of Animals for Scientific Purposes. Singapore.
34. Lin HS, Barua AB, Olson JA, Low KS, Chan SY, Shoon ML, Ho PC. 2001. Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). J Pharm Sci 90:2023-2031.
35. Lin HS, Chan SY, Low KS, Shoon ML, Ho PC. 2000. Kinetic study of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration. J Pharm Sci 89:260-267.
36. Lin HS, Leong WW, Yang JA, Lee P, Chan SY, Ho PC. 2007. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. Int J Pharm 341:238-245.
37. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Advan Anal Chem Instr 4:117-212.
38. Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
39. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. 2007. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol 3:469-489.
40. Chan OH, Stewart BH. 1996. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1:461-473.
41. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W. 2004. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12:5571-5578.
42. Ma N, Liu WY, Li HD, Jiang XY, Liu W, Liu X, Deng CF, Zhang BK, Xiang DX. 2008. High-performance liquid chromatographic analysis of resveratrol analog 3, 5, 4'-trimethoxystilbene in rat plasma. Methods Find Exp Clin Pharmacol 30:215-220.
43. Ma N, Liu WY, Li HD, Jiang XY, Zhang BK, Zhu RH, Wang F, Xie YL, Zhou XQ, Wu X, Xiang DX. 2007. RP-HPLC study of resveratrol derivative (BTM-0512) in rat plasma and tissue distribution. Yao Xue Xue Bao 42:1183-1188.
44. Sarpietro MG, Spatafora C, Tringali C, Micieli D, Castelli F. 2007. Interaction of resveratrol and its trimethyl and triacetyl derivatives with biomembrane models studied by differential scanning calorimetry. J Agric Food Chem 55:3720-3728.
45. Sarpietro MG, Ottimo S, Giuffrida MC, Spatafora C, Tringali C, Castelli F. 2010. beta-Cyclodextrins influence on E-3, 5, 4'-trimethoxystilbene absorption across biological membrane model: a differential scanning calorimetry evidence. Int J Pharm 388:144-150.
46. Arima H, Yunomae K, Hirayama F, Uekama K. 2001. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther 297:547-555.
47. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
48. Das S, Lin HS, Ho PC, Ng KY. 2008. The Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol. Pharm Res 25:2593-2600.
49. Lin HS, Yue BD, Ho PC. 2009. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed Chromatogr 23:1308-1315.
50. Remsberg CM, Yanez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. 2008. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 22:169-179.
51. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. 2010. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol.
52. Lin HS, Tringali C, Spatafora C, Wu C, Ho PC. 2010. A simple and sensitive HPLC-UV method for the quantification of piceatannol analog trans-3, 5, 3', 4'-tetramethoxystilbene in rat plasma and its application for a pre-clinical pharmacokinetic study. J Pharm Biomed Anal 51:679-684.
53. Lin HS, Choo QY, Ho PC. 2010. Quantification of oxyresveratrol analog trans-2, 4, 3', 5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study. Biomed Chromatogr 24:1373-1378.
54. Lin HS, Zhang W, Go ML, Tringali C, Spatafora C, Ho PC. 2011. Quantification of trans-3, 4, 5, 4'-Tetramethoxystilbene in Rat Plasma by HPLC: Application to Pharmacokinetic Study. J Agric Food Chem 59:1072-1077.
55. Lin HS, Tringali C, Spatafora C, Choo QY, Ho PC. 2010. LC determination of trans-3, 5, 3', 4', 5'-pentamethoxystilbene in rat plasma. Chromatographia 72:827-832.
56. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay JF, Brouillard R, Raul F. 2003. Resveratrol analog (Z)-3, 5, 4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107:189-196.
57. Pettit GR, Grealish MP, Jung MK, Hamel E, Pettit RK, Chapuis JC, Schmidt JM. 2002. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem 45:2534-2542.
58. Chabert P, Fougerousse A, Brouillard R. 2006. Anti-mitotic properties of resveratrol analog (Z)-3, 5, 4'-trimethoxystilbene. Biofactors 27:37-46.
59. Mazue F, Colin D, Gobbo J, Wegner M, Rescifina A, Spatafora C, Fasseur D, Delmas D, Meunier P, Tringali C, Latruffe N. 2010. Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs. Eur J Med Chem 45:2972-2980.
60. Lin HS, Zhang W, Go ML, Choo QY, Ho PC. 2010. Determination of Z-3, 5, 4'-trimethoxystilbene in rat plasma by a simple HPLC method: Application in a pre-clinical pharmacokinetic study. J Pharm Biomed Anal 53:693-697.